Abstract
Natulan is a new cytostatic of the group of methylhydrazine derivatives. It has been tried out on 18 patients with Hodgkin's disease and in 3 patients with reticulum cell sarcoma. In 78% of Hodgkin's disease cases, more or less complete remissions were obtained which puts Natulan among the most effective cytostatics. Remissions have also been noted in 2 cases of reticulum cell sarcoma. The most favourable properties of Natulan are the rapid therapeutic effect, the possibility of peroral administration and the absence of cross-resistance with other cytostatics. The authors insist on the possibility of prophylaxis of the recurrences by a cytostatic treatment of out-patients with Natulan. Side effects, among which a tendency to nausea and the possibility of granulopenia and thrombopenia which can appear late in prolonged treatments, are discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
